Trial Profile
Predictors of Response to Augmentation With Ziprasidone (Geodon) in Major Depressive Disorder : A 13-week, Double-Blind, Placebo-Controlled, Cross-Over Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Ziprasidone (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 04 Aug 2010 New trial record